New York University has shut down eight clinical trials for PTSD involving an experimental drug designed to synthetically imitate the effects of cannabis. A similar drug was found to be responsible for the death of one French study participant in January.
After showing that people suffering from post-traumatic stress disorder have an imbalance in their endocannabinoid system, Alexander Neumeister, then the director of the molecular imaging program in the Departments of Psychiatry and Radiology at NYU School of Medicine, got the go-ahead from NYU, and the funding from pharmaceutical giant Pfizer, to run a clinical trial on a poorly understood class of drugs known as FAAH inhibitors.
FAAH inhibitors interact with the body’s natural endocannabinoid by preventing it from degrading anandamide, a neurotransmitter generated in the body to activate cannabinoid receptors. Researchers from many different fields are attempting to use these drugs